Drug Prices
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to discounted drug prices unless they comply with new data submission requirements.
The administration Apri 23 reached a most-favored-nation drug pricing agreement with Regeneron, the maker of the popular cholesterol medicine Praluent. This is the 17th such agreement by a drug manufacturer with the Trump administration, and it ensures Regeneron’s prices are in line with the lowest…
The Centers for Medicare & Medicaid Services announced in a memo April 21that it is delaying implementation of the Medicare Part D portion of the Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth Model, or BALANCE, for 2027 pending further evaluation and data collection.
The U.S. Court of Appeals for the 5th Circuit today affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin enforcement of the state’s law protecting 340B pricing for contract pharmacy arrangements.
The AHA released the 2026 edition of its annual Costs of Caring report. It shows hospitals and health systems continue to face increases in the costs of people, supplies, medicines and infrastructure needed to provide care and services to their communities.
This Costs of Caring report provides a data-driven assessment of the financial realities faced by hospitals and health systems, and underscores why sustainable affordability solutions must address the structural drivers of cost growth rather than focusing narrowly on hospital prices alone.
This report outlines the key trends impacting hospital financial stability in 2025.
The Trump administration has announced a number of agreements with drug companies to lower U.S. drug prices to levels similar to other countries’, and has proposed several new drug payment models through the Center for Medicare & Medicaid Innovation (CMMI).
The AHA commented today on the Centers for Medicare & Medicaid Services’ proposed rule on the Global Benchmark for Efficient Drug Pricing Model, or GLOBE, a new mandatory Medicare payment model issued in December. The model seeks to make most-favored-nation prices available…
The issue of affordability, including health care affordability, is front and center this year and will be part of this year's congressional and administration discussions, as well as the mid-term elections.